Arcadia Biosciences (RKDA) Stock Price, News & Analysis

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Arcadia Biosciences in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" RKDA shares.
View RKDA analyst ratings or view top-rated stocks.

1 Wall Street research analysts have issued 12 month price objectives for Arcadia Biosciences' stock. Their RKDA share price targets range from $10.00 to $10.00. On average, they predict the company's share price to reach $10.00 in the next year. This suggests a possible upside of 385.4% from the stock's current price.
View analysts price targets for RKDA or view top-rated stocks among Wall Street analysts.

Arcadia Biosciences' stock was trading at $3.13 at the start of the year. Since then, RKDA stock has decreased by 34.2% and is now trading at $2.06.
View the best growth stocks for 2024 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our RKDA earnings forecast.

Arcadia Biosciences, Inc. (NASDAQ:RKDA) released its earnings results on Monday, November, 15th. The basic materials company reported ($0.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.13. The basic materials company earned $2.38 million during the quarter, compared to analysts' expectations of $2.73 million. Arcadia Biosciences had a negative trailing twelve-month return on equity of 81.56% and a negative net margin of 246.80%. During the same quarter in the previous year, the business earned ($0.54) EPS.

Arcadia Biosciences shares reverse split on the morning of Wednesday, January 24th 2018. The 1-20 reverse split was announced on Tuesday, January 23rd 2018. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, January 23rd 2018. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

1 employees have rated Arcadia Biosciences Chief Executive Officer Matthew Plavan on Glassdoor.com. Matthew Plavan has an approval rating of -100% among the company's employees. This puts Matthew Plavan in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Arcadia Biosciences investors own include Bionano Genomics (BNGO), ADMA Biologics (ADMA), Zosano Pharma (ZSAN), Gran Tierra Energy (GTE), Matinas BioPharma (MTNB), Organigram (OGI), Pennsylvania Real Estate Investment Trust (PEI), Novan (NOVN), CNBX Pharmaceuticals (CNBX) and Enerplus (ERF).

Arcadia Biosciences (RKDA) raised $66 million in an IPO on Friday, May 15th 2015. The company issued 8,200,000 shares at $8.00 per share. Credit Suisse, J.P. Morgan and Piper Jaffray served as the underwriters for the IPO.

Shares of RKDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.